Charles Schwab Investment Management Inc. Cuts Stake in Agenus Inc. (NASDAQ:AGEN)

Charles Schwab Investment Management Inc. trimmed its stake in Agenus Inc. (NASDAQ:AGEN) by 64.7% in the third quarter, Holdings Channel.com reports. The firm owned 55,954 shares of the biotechnology company’s stock after selling 102,763 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Agenus were worth $307,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Federated Hermes Inc. acquired a new position in shares of Agenus in the 2nd quarter valued at $1,921,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Agenus in the 2nd quarter worth $106,000. Point72 DIFC Ltd acquired a new position in Agenus in the second quarter valued at $51,000. Squarepoint Ops LLC purchased a new stake in Agenus during the second quarter valued at about $614,000. Finally, Blair William & Co. IL purchased a new stake in Agenus during the second quarter valued at about $441,000. 61.46% of the stock is currently owned by hedge funds and other institutional investors.

Agenus Trading Up 1.8 %

Shares of Agenus stock opened at $2.76 on Friday. Agenus Inc. has a twelve month low of $2.50 and a twelve month high of $19.69. The stock has a market cap of $64.75 million, a price-to-earnings ratio of -0.25 and a beta of 1.24. The company has a fifty day moving average price of $3.67 and a 200 day moving average price of $7.16.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of Agenus in a research note on Thursday, December 5th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and one has issued a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $10.00.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.